Now there is no cure for the degenerative neurological disease and standard therapies just manage the side effects of tremors and body stiffness, but do not prevent brain cells from dying.
"This is a very promising finding, as the drug holds potential to affect the course of the disease itself, and not merely the symptoms", said the study's senior author, Professor Tom Foltynie (UCL Institute of Neurology).
Parkinson's disease, which affects 127,000 people in the United Kingdom, causes progressive damage to the brain over time and cells that produce dopamine hormone - a chemical that helps control body movement - are lost. It leads difficulty moving and eventually memory problems.
The drugs administered now, work to boost dopamine levels and replace the hormone being lost, but is powerless to stop the brain continuing to die.
First author Dr Dilan Athauda said there was still more work to be done before the drug could be approved as a Parkinson's treatment.
No drug stops that happening.
It has been reported that half of the patients were provided with the drug exenatide and the others were provided with placebo during the trial.
Glu Mobile (NASDAQ:GLUU) Earning Somewhat Positive Media Coverage, Study Finds
Revenue for the quarter also did not kill consensus, coming in at $68.68 Million, compared to the consensus of 72.06 Million. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link .
Vatican calls on Maduro to scrap plans to alter Constitution
Two days after the vote, security forces raided the homes of opposition members Leopoldo Lopez and Antonio Ledezma. A full audit would be needed to confirm the exact numbers, he said.
Channing Tatum: My daughter Everly doesn't like 'Step Up'
You're going to do it too ", Halle continued, prompting Jenna to quip, "This is typical, I'm getting his payback. "You liked it. That's because Everly would definitely approve.
Three months after the experimental treatment stopped, those who had been taking exenatide showed better brain health than those who did not.
The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF), followed 60 patients with Parkinson's disease being treated at the National Hospital for Neurology and Neurosurgery (NHNN).
"We have to be excited and encouraged, but also cautious as we need to replicate these findings". Further, longer-term trials are required.
People with Parkinson's who took Exenatide - an existing diabetes medication - for around a year had better motor skills than those who took a placebo.
Those sensors are found in brain cells too.
According to a new research, diabetes drug may be useful to treat those suffering from Parkinson's disease. It is thought the drug makes those cells work more efficiently or helps them to survive.
David Dexter, the deputy director of research at Parkinson's United Kingdom, said: "The findings offer hope that drugs like exenatide can slow the course of Parkinson's - something no current treatment can do".
'The results from the Exenatide studies justify continued testing, but clinicians and patients are urged not to add Exenatide to their regimens until more is known about their safety and impact on Parkinson's'.